Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1,429.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
1,431.20 1,432.80
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.00 6,221.00 93.90 15.2 71,894
Last Trade Time Trade Type Trade Size Trade Price Currency
08:54:00 O 1,827,981 1,406.00 GBX

Glaxosmithkline (GSK) Latest News (2)

More Glaxosmithkline News
Glaxosmithkline Investors    Glaxosmithkline Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BMO UK HIGH INCOME TRUST PLC 5.30% 2021-07-31

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline Forums and Chat

Date Time Title Posts
23/9/202108:07Glaxosmithkline - The recovery28,465
24/8/202113:00GlazoSmithKline - News & Information75
02/7/202110:58GSK - just mucking around-
23/1/202114:27In Rude Health!1

Add a New Thread

Glaxosmithkline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-09-22 15:29:401,428.80961,371.65AT
2021-09-22 15:29:401,428.601,15016,428.90AT
2021-09-22 15:29:401,428.604506,428.70AT
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,429p.
Glaxosmithkline Plc has a 4 week average price of 1,377.40p and a 12 week average price of 1,377.40p.
The 1 year high share price is 1,528.80p while the 1 year low share price is currently 1,190.80p.
There are currently 5,031,076,193 shares in issue and the average daily traded volume is 10,216,765 shares. The market capitalisation of Glaxosmithkline Plc is £71,894,078,797.97.
spacecake: Ten year returns GlaxoSmithKline PLC 5.44% FTSE 100 TR GBP 6.7% Took a quick look at GSK 10 year record on Morningstar, it tells the tale quite clearly, over a ten year period there has been no growth as ebit has fallen, operating profit has fallen, low revenue growth (25%), expenses growth (40%), exceptional items has doubled, no eps growth. The share price has wiggled around a lot over that period and the company paid a dividend for those that love dividends. It would be easy to not get excited for those that love to not be excited. hTTps://tools.morningstar.co.uk/uk/stockreport/default.aspx?tab=10&vw=is&;SecurityToken=0P00007OD0%5D3%5D0%5DE0WWE%24%24ALL&Id=0P00007OD0&ClientFund=0&CurrencyId=BAS&orderType=ascending&rounding=2&view=0&period=10
geckotheglorious: "Narrower drug pricing bill introduced in House by centrist Democrats" A new bill introduced in the House by a handful of centrist Democrats would allow the federal government to negotiate drug prices for Medicare, but only for drugs that have no competition. The bill, the Reduced Costs and Continued Cures Act, was introduced by Rep. Scott Peters (Calif.) and Kurt Schrader (Ore.). Reps. Kathleen Rice (N.Y.), Stephanie Murphy (Fla.), and Lou Correa (Calif.) are co-sponsors. The proposed legislation could through a wrench into legislation that is backed by Democratic leadership, which would allow price negotiation by Medicare on nearly all drugs. An out-of-pocket maximum cap on prescription drug expenditure would be set for Medicare beneficiaries based on an individual's Federal Poverty Level standing. Regarding the drug price lowering in the narrower band of eligible drugs, the Peters/Schrader bill would allow HHS to negotiate price concessions between 25% and 35%. It would base beneficiary cost-sharing on the post-rebate price of a drug rather than the original list price to further reduce the cost burden on patients. It also sets a $50 out-of-pocket maximum on insulin per month. hTTps://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats House committee approves portion of spending package that includes drug price negotiation The provision would also cap price increases on some drugs at the inflation rate. hTTps://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?
spud: A Big Pharma CEO Is Battling Wall Street’s Most Feared Fund http://www.bloomberg.com/news/features/2021-09-07/feared-wall-street-fund-elliott-is-targeting-gsk-what-does-it-want GSK’s Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from. One afternoon in mid-April, Emma Walmsley, the chief executive officer of GlaxoSmithKline Plc, logged into what could be one of the most important video conferences of her career. A few days earlier Elliott Investment Management, the U.S.-based activist fund, had contacted the drugmaker’s chairman, Jonathan Symonds, with some alarming news. Without GSK’s knowledge, Elliott had been quietly buying up billions of dollars of its shares. Now Gordon Singer, a managing partner at the firm and the son of its founder, Paul Singer, was going to explain why, and what Elliott wanted. No corporate leader relishes a call from Elliott, one of the most aggressive investors on the planet, with a long track record of forcing sales or breakups, ousting CEOs, overhauling boards—and even, on one occasion, seizing an Argentine naval vessel over a debt dispute. Walmsley and Symonds, however, were trying to be open-minded about what Singer had to say; under the circumstances, they didn’t have much choice. Over the next hour, Singer and a colleague, Sebastien De La Riviere, walked the GSK executives through a detailed presentation on their company. It followed a standard Elliott playbook, outlining what the fund viewed as a series of failings over the years, combined with examples of unflattering commentary from shareholders it had interviewed in the months it spent accruing its stake. Walmsley and Symonds listened politely. But no one on either side of the call was under any illusions: Elliott had just issued a direct challenge to Walmsley’s leadership. For the 52-year-old CEO, that represented a serious problem. Arguably the highest-profile female executive in Britain, Walmsley was partway through an elaborate effort to transform her vast company, spinning off its consumer business—the maker of Advil, Sensodyne, and Nicorette, among two dozen products—from the core pharmaceutical operation. Defending against an assault by Elliott was not part of the plan. And she’d be doing it in public: hours before the meeting, the Financial Times had revealed that Elliott was targeting GSK............. spud
montyhedge: I held GSK for years, nice dividend that's all, trouble is no capital growth. Some shares like Clarkson Plc the shipping broker 3000% shareprice growth in 25 years, 18 years of continuous dividend growth. GSK below it shareprice of 25 years ago and dividend being cut next year and you boys love GSK don't get it.
lovewinshatelosses: With the current management team, BH, I would not be surprised if they gave it away for free, assuming they do not trip up again. What is wrong with the pfizer approach, by the way? A first (and indeed legally binding) duty of any listed company is to its shareholders. You only have to look at the (frankly ungrateful) reception Astra got from a few politicians across the world, to see the mantra of no good deed going unpunished play out, so we might as well cash in, if we get it right this time! Anyway, FWIW, I see the current share price weakness as being more to do with slight stirling strength against the dollar, rather than anything GSK-specific at this stage. I unloaded a few in the 15's but still have (for me) a fairly sizeable holding here, for now.
bountyhunter: Actually this is a bit better... NYSE:GSK:.. NYSE:GSK price and chart added to the header.
gibbs1: TraderMichael 13 Aug '21 - 10:49 - 28168 of 28168 0 0 0 Expresses the views of many of us ..... Https://seekingalpha.com/article/4448494-glaxosmithkline-is-relatively-undervalued-and-spin-off-to-unlock-value Last Remarks GSK's spin-off is a positive development for the company. Our investment thesis did not change since our last article. More focused companies and greater transparency will lead to a change in sentiment. GSK is 30%+ undervalued relative to its peers. Shareholders will benefit from a well-covered dividend and capital appreciation. Currently, there is a negative sentiment around GSK, and rightly so given management has not been transparent and following the dividend cut. However, GSK currently offers a good margin of safety as the company is priced around worst-case scenarios. Management has positioned the company in such a way to create significant value for shareholders in the coming years, however in the past they did not deliver. We now monitor their execution and expect shareholders to benefit from growing dividend and capital appreciation. We remain bullish and buy at current price levels of £14.4.
netcurtains: sppole5: If the price goes down a notch due to your comment it will be your fault. Be positive, we're in an uptrend. Go GSK - you can do it ! Yes you can! GSK GSK GSK ✔✔ 004;✔✔✔✔ 004;✔✔✔✔
charlie9038: Im with netcurtains on this: GSK now trades on a price-to-sales ratio of 2x and a free cash flow yield of 10%. What really matters is that a 10% free cashflow yield is extremely attractive in a low interest rate environment. Even if a lot of things went badly, GSK would be able to keep operating, invest in its businesses and still reward shareholders. If the new structure is successful, and bearing in mind GSK’s valuation compared with those of other leading pharmaceutical companies, GSK has the potential to double in price. Lets keep the news & banter positive, GLA
netcurtains: grahamburn: I disagree. An expert investor reads. The more the TRUE positive story of GSK is promoted the more expert investors (such as myself) will notice that GSK is about the best bargain on the FTSE100 stock market today. I have all sorts of computer systems, and analysis on my computer (I have 30 odd years experience coding databases and algorithms). All signals point to GSK exploding north within 18 months. Its not very simple - it really is not. Its complex. We all need to shout, on ADVFN, TWITTER, share magazines, letters - it is the cumulative affect of chatter that influences people to LOOK AT THE BALANCE SHEETS and RNS and see the facts. GSK is best bargain on FTSE100. just ONE article in the Sunday Times can often lead to a share rising 5% even a FTSE100 share. Chatter is important.
Glaxosmithkline share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210923 07:12:57